There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insmed (INSM – Research Report), Regulus (RGLS – Research Report) and Heron Therapeutics (HRTX – Research Report) with bullish sentiments. Insmed (INSM) In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Insmed, with a price target of $55.00. The company's shares closed last Monday at $22.30, close to its 52-week low of $21.09. According to TipRanks.
https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-83?utm_source=advfn.com&utm_medium=referral
Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Regulus Therapeutics Charts.
Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Regulus Therapeutics Charts.